Afficher la notice abrégée

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

dc.relation.isnodouble946e0e8d-767d-4041-8522-a7597c09ddc5*
dc.contributor.authorNEAL, Bruce
dc.contributor.authorPERKOVIC, Vlado
dc.contributor.authorMAHAFFEY, Kenneth W.
dc.contributor.authorDE ZEEUW, Dick
dc.contributor.authorFULCHER, Greg
dc.contributor.authorERONDU, Ngozi
dc.contributor.authorSHAW, Wayne
dc.contributor.authorLAW, Gordon
dc.contributor.authorDESAI, Mehul
dc.contributor.authorMATTHEWS, David R.
dc.contributor.authorCATARGI, Bogdan
dc.contributor.authorGRP, Canvas Program Collaborative
dc.date.accessioned2020-07-09T14:16:41Z
dc.date.available2020-07-09T14:16:41Z
dc.date.issued2017-08-17
dc.identifier.issn0028-4793
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/10283
dc.description.abstractEnBACKGROUND Canagliflozin is a sodium-glucose cotransporter 2 inhibitor that reduces glycemia as well as blood pressure, body weight, and albuminuria in people with diabetes. We report the effects of treatment with canagliflozin on cardiovascular, renal, and safety outcomes. METHODS The CANVAS Program integrated data from two trials involving a total of 10,142 participants with type 2 diabetes and high cardiovascular risk. Participants in each trial were randomly assigned to receive canagliflozin or placebo and were followed for a mean of 188.2 weeks. The primary outcome was a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. RESULTS The mean age of the participants was 63.3 years, 35.8% were women, the mean duration of diabetes was 13.5 years, and 65.6% had a history of cardiovascular disease. The rate of the primary outcome was lower with canagliflozin than with placebo (occurring in 26.9 vs. 31.5 participants per 1000 patient-years; hazard ratio, 0.86; 95% confidence interval [CI], 0.75 to 0.97; P< 0.001 for noninferiority; P = 0.02 for superiority). Although on the basis of the prespecified hypothesis testing sequence the renal outcomes are not viewed as statistically significant, the results showed a possible benefit of canagliflozin with respect to the progression of albuminuria (hazard ratio, 0.73; 95% CI, 0.67 to 0.79) and the composite outcome of a sustained 40% reduction in the estimated glomerular filtration rate, the need for renal-replacement therapy, or death from renal causes (hazard ratio, 0.60; 95% CI, 0.47 to 0.77). Adverse reactions were consistent with the previously reported risks associated with canagliflozin except for an increased risk of amputation (6.3 vs. 3.4 participants per 1000 patient-years; hazard ratio, 1.97; 95% CI, 1.41 to 2.75); amputations were primarily at the level of the toe or metatarsal. CONCLUSIONS In two trials involving patients with type 2 diabetes and an elevated risk of cardiovascular disease, patients treated with canagliflozin had a lower risk of cardiovascular events than those who received placebo but a greater risk of amputation, primarily at the level of the toe or metatarsal.
dc.title.enCanagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
dc.typeArticle de revue
dc.identifier.doi10.1056/NEJMoa1611925
dc.subject.halChimie/Matériaux
bordeaux.journalNew England Journal of Medicine
bordeaux.page644-657
bordeaux.volume377
bordeaux.hal.laboratoriesInstitut de Chimie & de Biologie des Membranes & des Nano-objets (CBMN) - UMR 5248*
bordeaux.hal.laboratoriesInstitut de Chimie & de Biologie des Membranes & des Nano-objets (CBMN, UMR 5248)
bordeaux.issue7
bordeaux.institutionUniversité de Bordeaux
bordeaux.institutionBordeaux INP
bordeaux.COinSctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft.jtitle=New%20England%20Journal%20of%20Medicine&amp;rft.date=2017-08-17&amp;rft.volume=377&amp;rft.issue=7&amp;rft.spage=644-657&amp;rft.epage=644-657&amp;rft.eissn=0028-4793&amp;rft.issn=0028-4793&amp;rft.au=NEAL,%20Bruce&amp;PERKOVIC,%20Vlado&amp;MAHAFFEY,%20Kenneth%20W.&amp;DE%20ZEEUW,%20Dick&amp;FULCHER,%20Greg&amp;rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée